Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Total Debt Summary of Arcus Biosciences, Inc.

  • Arcus Biosciences, Inc.'s latest annual total debt in 2023 was 11 Million USD , down -90.83% from previous year.
  • Arcus Biosciences, Inc.'s latest quarterly total debt in 2024 Q1 was 11 Million USD , down 0.0% from previous quarter.
  • Arcus Biosciences, Inc. reported annual total debt of 120 Million USD in 2022, up 2.66% from previous year.
  • Arcus Biosciences, Inc. reported annual total debt of 116.88 Million USD in 2021, up 666.82% from previous year.
  • Arcus Biosciences, Inc. reported quarterly total debt of 11 Million USD for 2024 Q2, down 0.0% from previous quarter.
  • Arcus Biosciences, Inc. reported quarterly total debt of 9 Million USD for 2023 Q3, down -92.24% from previous quarter.

Annual Total Debt Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Total Debt of Arcus Biosciences, Inc. (2023 - 2016)

Year Total Debt Total Debt Growth
2023 11 Million USD -90.83%
2022 120 Million USD 2.66%
2021 116.88 Million USD 666.82%
2020 15.24 Million USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%

Peer Total Debt Comparison of Arcus Biosciences, Inc.

Name Total Debt Total Debt Difference
ADC Therapeutics SA 124.37 Million USD 91.156%
Alto Neuroscience, Inc. 151.46 Million USD 92.738%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 30.87 Million USD 64.375%
Ginkgo Bioworks Holdings, Inc. 241.76 Million USD 95.45%
Nuvation Bio Inc. 4 Million USD -174.52%
Nuvation Bio Inc. 4 Million USD -174.52%
Theriva Biologics, Inc. 2.15 Million USD -410.678%
Zymeworks Inc. 26.72 Million USD 58.835%